Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Arcturus Therapeutics Holdings Inc. ARCT
$30.81
-$1.48 (-4.79%)
На 18:01, 12 мая 2023
-36.71%
Потенциал через год
Ранг: 2
Ключевые показатели
-
Marketcap
878172780.00000000
-
week52high
33.80
-
week52low
11.70
-
Revenue
-244000
-
P/E TTM
73
-
Beta
2.60692000
-
EPS
0.33000000
-
Last Dividend
0.05960000
-
Next Earnings Date
09 мая 2023 г. в 20:00
Описание компании
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus; Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for rare disease targets; CureVac AG to develop mRNA therapeutic and vaccine candidates for various indications; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc. to discover siRNA medicines for the treatment of non-alcoholic steatohepatitis. The company was founded in 2013 and is headquartered in San Diego, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Wells Fargo | Overweight | Overweight | 10 авг 2022 г. |
| Raymond James | Underperform | Market Perform | 10 авг 2022 г. |
| Barclays | Underweight | Underweight | 10 авг 2022 г. |
| Goldman Sachs | Sell | Sell | 24 мая 2022 г. |
| Goldman Sachs | Sell | Sell | 11 мая 2022 г. |
| Citigroup | Buy | Neutral | 03 ноя 2022 г. |
| Cantor Fitzgerald | Overweight | Overweight | 02 ноя 2022 г. |
| Barclays | Equal-Weight | Underweight | 02 ноя 2022 г. |
| Goldman Sachs | Sell | Sell | 10 ноя 2022 г. |
| Baird | Underperform | Neutral | 10 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Marquet Magda | A | 24942 | 2222 | 15 дек 2022 г. |
| Kummerfeld Keith C | A | 40000 | 40000 | 09 дек 2022 г. |
| SASSINE ANDY | A | 125000 | 125000 | 09 дек 2022 г. |
| Kurata Lance | A | 125000 | 125000 | 09 дек 2022 г. |
| Chivukula Pad | A | 125000 | 125000 | 09 дек 2022 г. |
| Payne Joseph E | A | 250000 | 250000 | 09 дек 2022 г. |
| Markels John | A | 6986 | 6986 | 08 дек 2022 г. |
| Markels John | A | 20000 | 20000 | 08 дек 2022 г. |
| Payne Joseph E | A | 1480097 | 5000 | 23 ноя 2022 г. |
| SASSINE ANDY | A | 269303 | 1068 | 15 авг 2022 г. |
Новостная лента
Arcturus Therapeutics (ARCT) Q1 Earnings and Revenues Miss Estimates
Zacks Investment Research
09 мая 2023 г. в 19:07
Arcturus Therapeutics (ARCT) came out with quarterly earnings of $0.88 per share, missing the Zacks Consensus Estimate of $2.92 per share. This compares to loss of $1.94 per share a year ago.
What To Know About ‘Arcturus': New Covid Variant Causing Pink Eye
Forbes
27 апр 2023 г. в 18:07
New Covid strain XBB.1.18, nicknamed arcturus, is quickly spreading across the U.S., but experts are warning that pink eye and high fever, two symptoms of the new variant, are particularly present among children.
Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 9, 2023
Business Wire
26 апр 2023 г. в 08:30
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 9, 2023.
Unlocking Arcturus' Potential And De-Risking Through Partnerships
Seeking Alpha
11 апр 2023 г. в 13:03
Arcturus is executing well, utilizing strategic partnerships with CSL and Meiji to de-risk its financial position. The company has reinforced its management team by appointing a CMO and CDO, bringing valuable experience to the company's pipeline development.
Why Arcturus Therapeutics Stock Is Soaring Today
The Motley Fool
29 мар 2023 г. в 11:45
Arcturus beat expectations with its Q4 results. The company also provided an encouraging update on its pipeline programs.